PCVX · NASDAQ · STOCK
Vaxcyte (PCVX) Stock Analysis
$71.37
52W $39.87 – $90.75
65/100
$10.31B
-9.3
1.23
Is PCVX Bullish or Bearish?
Bullish.
Innellis AI committee rates Vaxcyte, Inc. (PCVX) Buy with a composite score of 65/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.68 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.32 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 34.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
65/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 3%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -37.6% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Price trading above the upper Bollinger Band -- stretched
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 34.8% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 51 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 65.3 to 65.3.
- New bearish signals: 3 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +2 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
68.1
Neutral
MACD Histogram
1.323
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
1.01
Above Upper Band
Price vs Moving Averages
EMA 9
$64.84
Above
EMA 21
$62.07
Above
EMA 50
$59.99
Above
EMA 200
$55.62
Above
Fundamental Analysis
Valuation
89
Growth
48
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-9.3×
P/B Ratio
3.74×
PEG Ratio
0.18
Dividend Yield
0.00%
52W High
$90.75
52W Low
$39.87
Quality & Growth
ROE
-2854.7%
ROA
-2516.9%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.04
AI Fundamental Assessment
P/E ratio of -9.3 (inexpensive relative to a 15-40x range); Price-to-book of 3.7x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -28.5%; Return on assets of -25.2%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 5.72 (healthy short-term liquidity); Debt-to-equity of 0.04; Free cash flow per share is negative (-8.32); Most recent quarter beat estimates by 6.0%; EPS growth accelerating (-27.8% -> +14.3% QoQ); Analyst estimates falling over recent quarters
Get the Full PCVX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →